Background/Aims Hepatocellular carcinoma (HCC) is a prevalent form of primary liver cancer and the fifth leading cause of worldwide cancer mortality. Though early diagnosis of HCC is important, so far lack of effective biomarkers for early diagnosis of HCC has been a problem. In this study, we searched for potential functional biomarkers of alcoholic HCC by using metagenomics approach.
Methods Between September 2017 and April 2019, normal control (n=44), alcoholic liver cirrhosis (n=44), and alcoholic HCC (n=13) groups were prospectively enrolled and analyzed. Gut microbiota was analyzed using the 16S-based microbiome taxonomic profiling platform of EzBioCloud Apps and analyzing system.
Results There was a statistically significant difference among groups in diversity (P<0.05). In the comparison of phylum between cirrhosis and HCC, Proteobacteria were increased and Bacteroidetes were decreased. Firmicutes were not significantly different among the three groups. In the taxonomic profiling, relative abundance of Lactobacillus in the cirrhosis and HCC groups showed richness (P<0.05). In the biomarker analysis between cirrhosis and HCC, obiquinome Fe-S protein 3, global nitrogen regulator, Vesicle-associated membrane protein 7, toxin YoeB, peroxisome-assembly ATPase, and nitrogen oxide reductase regulator were differently expressed (P<0.001).
Conclusions Alcoholic HCC showed different expressions in the stool taxonomy and biomarker compared with that of cirrhosis and control. Therefore, new biomarkers using stool analysis for alcoholic HCC are necessary.
Citations
Citations to this article as recorded by
Composition of gut microbiota and alcohol-related liver disease: A systematic review and meta-analysis Xuanxuan Niu, Lei Ma, Zhewen Zhou, Yan Li, Anyi Shi, Lihan Weng, Huichun Xing Drug and Alcohol Dependence.2026; 278: 112988. CrossRef
Gut microbiome and bile acid metabolism in liver disease: Mechanisms, clinical implications, and therapeutic opportunities Huiping Zhou, Yi Huang, Chen Chen, Meiyi Song, Phillip B. Hylemon Pharmacological Reviews.2026; 78(2): 100120. CrossRef
Lactobacillaceae in Acute and Chronic Liver Diseases: From Microbiota Modulation to Therapeutic Potential Xulan Zhang, Yi Xia, Feng Ji Probiotics and Antimicrobial Proteins.2026;[Epub] CrossRef
A Systematic Review of Microbiota in Cirrhosis: A Change Towards a More Pathogenic Predisposition Elias Xirouchakis, Alexandros Pelekanos, Spyridon Xirouchakis, Hariklia Kranidioti, Spilios Manolakopoulos International Journal of Molecular Sciences.2025; 26(2): 527. CrossRef
Distinct Gut Microbiota Profiles Associated with Advanced Hepatocellular Carcinoma in a Thai Cohort: A 16S rRNA Sequencing Study Thanakorn Charoenthanadhol, Jutarop Phetcharaburanin, Theerayut Bubpamala, Aumkhae Sookprasert, Jarin Chindaprasirt, Thanachai Sanlung, Piyakarn Watcharenwong, Siraphong Putraveephong, Kosin Wirasorn Cancers.2025; 17(17): 2915. CrossRef
Prognostic Role of Short-Chain Fatty Acid-Producing Gut Microbiota and Gut Microbial Dynamics in Patients with Hepatocellular Carcinoma Receiving Chemoembolization: A Prospective Study Jiwon Yang, Jihye Lim, Eun Hye Kim, Jihyun An, Danbi Lee, Han Chu Lee, Jin-Yong Jeong, Ju Hyun Shim Journal of Hepatocellular Carcinoma.2025; Volume 12: 1991. CrossRef
Reuterin promotes pyroptosis in hepatocellular cancer cells through mtDNA-mediated STING activation and caspase 8 expression Lin Cui, Xiaohui Xu, Hui Fan, Xinyan Wan, Qian Chen, Junhui Zhang, Chuntao Tao, Zheng Du, Yitao Wang, Jian Zhang, Jun Zeng, Ying Zhang, Chundong Zhang, Longhao Li, Youquan Bu, Yunlong Lei Cancer Letters.2024; 601: 217183. CrossRef
Etiology-Dependent Microbiome Differences in Hepatocellular Carcinoma Development Nevena Todorovic, Serena Martinelli, Giulia Nannini, Ralf Weiskirchen, Amedeo Amedei International Journal of Molecular Sciences.2024; 25(24): 13510. CrossRef